How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...
Lucas Downey is the co-founder of MoneyFlows, and an Investopedia Academy instructor. Dr. JeFreda R. Brown is a financial consultant, Certified Financial Education Instructor, and researcher who has ...
Marshall Hargrave is a stock analyst and writer with 10+ years of experience covering stocks and markets, as well as analyzing and valuing companies. Michael Boyle is an experienced financial ...
What's CODE SWITCH? It's the fearless conversations about race that you've been waiting for. Hosted by journalists of color, our podcast tackles the subject of race with empathy and humor. We explore ...
December 31, 2025 • A few years back, many politicians were raising the alarm about the dangers of "CRT" in schools. Today, the new risk to public education is "DEI." What do both of these moments ...
An inherent principle of publication is that others should be able to replicate and build upon the authors' published claims. A condition of publication in a Nature Portfolio journal is that authors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback